Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer
Date
2006
Authors
Delea, T.
Karnon, J.
Smith, R.
Johnston, S.
Brandman, J.
Sung, J.
Goss, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
American Journal of Managed Care, 2006; 12(7):374-386
Statement of Responsibility
Delea, Thomas E.; Karnon, Jonathan; Smith, Robert E.; Johnston, Stephen R.D.; Brandman, Jane; Sung, Jennifer C.Y.; Goss, Paul E.
Conference Name
Abstract
Background: MA17 was a randomised placebo-controlled trial of letrozole 2.5 mg/day in 5187 estrogen receptor-positive, 50% node-negative, postmenopausal women (median age 62 years at enrolment) with early breast cancer, post-5 years Methods: A Markov model was used to estimate the incremental cost per QALY gained with extended adjuvant letrozole versus no therapy. Probabilities of disease progression and death were estimated using data from the MA17 study and other secondary sources. Costs of breast cancer care (letrozole therapy, surveillance, recurrences, terminal care) and treatment of osteoporosis and utilities were derived from literature. A full probabilistic sensitivity analysis was undertaken. The analysis was conducted from the perspective of the UK National Health Service (NHS) and cost estimates reflect 2004 values. All costs and outcomes were discounted at 3.5%. Results: Extended adjuvant letrozole resulted in a gain of 0.36 QALYs per patient (13.66 vs 13.30 with no therapy). These benefits were obtained at an additional expected lifetime cost of Lstg 3732 per patient (Lstg 10 Conclusion: Five years of letrozole therapy appears to be cost effective from the NHS perspective and should be considered in women with early breast cancer, following tamoxifen adjuvant therapy.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2004 American Society of Clinical Oncology